BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 55 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $9,984,341 | -11.9% | 10,025,000 | -13.0% | 0.00% | -100.0% |
Q1 2024 | $11,337,900 | -0.3% | 11,525,000 | 0.0% | 0.00% | 0.0% |
Q4 2023 | $11,377,555 | -6.2% | 11,525,000 | -7.6% | 0.00% | 0.0% |
Q3 2023 | $12,123,575 | -10.7% | 12,475,000 | -9.4% | 0.00% | 0.0% |
Q2 2023 | $13,572,708 | +36.9% | 13,775,000 | +42.0% | 0.00% | 0.0% |
Q1 2023 | $9,915,534 | -57.7% | 9,700,000 | -55.9% | 0.00% | 0.0% |
Q4 2022 | $23,431,502 | +112.1% | 22,000,000 | +98.2% | 0.00% | 0.0% |
Q3 2022 | $11,048,000 | +7.5% | 11,100,000 | +7.2% | 0.00% | 0.0% |
Q2 2022 | $10,276,000 | -6.2% | 10,350,000 | -5.3% | 0.00% | 0.0% |
Q1 2022 | $10,956,000 | -29.6% | 10,925,000 | -26.2% | 0.00% | 0.0% |
Q4 2021 | $15,573,000 | +7.9% | 14,800,000 | +5.7% | 0.00% | 0.0% |
Q3 2021 | $14,433,000 | +10.9% | 14,000,000 | +12.0% | 0.00% | 0.0% |
Q2 2021 | $13,020,000 | -4.0% | 12,500,000 | -5.5% | 0.00% | 0.0% |
Q1 2021 | $13,568,000 | -23.9% | 13,225,000 | -20.5% | 0.00% | 0.0% |
Q4 2020 | $17,825,000 | +22.2% | 16,625,000 | +19.2% | 0.00% | 0.0% |
Q3 2020 | $14,589,000 | +1.0% | 13,950,000 | +18.7% | 0.00% | 0.0% |
Q2 2020 | $14,448,000 | +9.7% | 11,750,000 | -7.1% | 0.00% | 0.0% |
Q1 2020 | $13,171,000 | -18.3% | 12,650,000 | -16.8% | 0.00% | 0.0% |
Q4 2019 | $16,115,000 | +7.4% | 15,200,000 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $15,005,000 | -2.9% | 15,200,000 | +2.4% | 0.00% | 0.0% |
Q2 2019 | $15,447,000 | +1.6% | 14,850,000 | +0.3% | 0.00% | 0.0% |
Q1 2019 | $15,202,000 | +2.0% | 14,800,000 | -1.3% | 0.00% | 0.0% |
Q4 2018 | $14,902,000 | -18.9% | 15,000,000 | -13.5% | 0.00% | 0.0% |
Q3 2018 | $18,375,000 | +9.8% | 17,350,000 | +5.5% | 0.00% | 0.0% |
Q2 2018 | $16,735,000 | +12.4% | 16,450,000 | +3.8% | 0.00% | 0.0% |
Q1 2018 | $14,889,000 | -1.5% | 15,850,000 | +5.0% | 0.00% | 0.0% |
Q4 2017 | $15,109,000 | -11.2% | 15,100,000 | -9.9% | 0.00% | 0.0% |
Q3 2017 | $17,006,000 | – | 16,750,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |
LOOMIS SAYLES & CO L P | 901,591 | $69,512,000 | 0.09% |